Literature DB >> 21742437

Modulation of immune response to Toxoplasma gondii in sheep by immunization with a DNA vaccine encoding ROP1 antigen as a fusion protein with ovine CD154.

Elżbieta Hiszczyńska-Sawicka1, Hong Li, Janet Boyu Xu, Lucyna Holec-Gąsior, Józef Kur, Richard Sedcole, Roy Bickerstaffe, Mirosław Stankiewicz.   

Abstract

CD154 is a cell surface molecule expressed by activated T cells. CD40 and CD154 interaction is critically important in regulating humoral and cell-mediated immune responses. In this study we have investigated whether a DNA vaccine encoding rhoptry protein 1 (ROP1) of Toxoplasma gondii, and encoding ovine CD154 induces an enhanced ROP1-specific immune response in sheep. Two groups of twelve animals received two intramuscular injections, of a DNA plasmid encoding T. gondii ROP1 antigen (group 1) or an ROP1 antigen fused to ovine CD154 (group 2). There were two control groups of sheep. One was injected with an empty vector (group 3) and the other received no injections at all (group 4). The injection of the plasmid containing ROP1 (group 1) at weeks 0 and 4 induced a significant IgG2 response at week 2 which was amplified at week 4 after the booster injection and persisted to week 8 compared to the control animals in groups 3 and 4. For IgG1, significant differences from the control animals were only observed from week 5 onwards. The fusion of CD154 and ROP1 elicited significant IgG1 and IgG2 responses from week 1 which were amplified from weeks 5 to 8 compared to the control animals in groups 3 and 4. The IgG1 response was significantly higher in group 2 animals receiving pROP1-CD154 compared to group 1 receiving pROP1 only. There was no significant difference in IgG2 responses between groups 1 and 2. Significant differences in IFN-γ levels were only observed in treatment group 1 at week 2 and treatment group 2 at weeks 1 and 2 compared to the control animals. The results demonstrated that an intramuscular injection of pROP1-CD154 gene to sheep significantly enhanced their immune response and induced a mixed Th1/Th2 response while the intramuscular injection of pROP1 only induced a Th1-specific immune response.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742437     DOI: 10.1016/j.vetpar.2011.06.010

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  7 in total

Review 1.  REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.

Authors:  Rosalie C Warner; Ryan C Chapman; Brianna N Davis; Paul H Davis
Journal:  J Parasitol       Date:  2021-11-01       Impact factor: 1.276

2.  Induction of Protective Immunity against Toxoplasmosis in BALB/c Mice Vaccinated with Toxoplasma gondii Rhoptry-1.

Authors:  Parthasarathy Sonaimuthu; Xiao T Ching; Mun Y Fong; Ramaswamy Kalyanasundaram; Yee L Lau
Journal:  Front Microbiol       Date:  2016-05-27       Impact factor: 5.640

3.  Immunogenicity of Multiepitope Vaccine Candidate against Toxoplasma gondii Infection in BALB/c Mice.

Authors:  Khalid Hajissa; Robaiza Zakaria; Rapeah Suppian; Zeehaida Mohamed
Journal:  Iran J Parasitol       Date:  2018 Apr-Jun       Impact factor: 1.012

4.  Scientific Opinion on the public health hazards to be covered by inspection of meat from sheep and goats.

Authors: 
Journal:  EFSA J       Date:  2013-06-27

Review 5.  Advances in vaccine development and the immune response against toxoplasmosis in sheep and goats.

Authors:  Tanjila Hasan; Yoshifumi Nishikawa
Journal:  Front Vet Sci       Date:  2022-08-25

Review 6.  Use of Veterinary Vaccines for Livestock as a Strategy to Control Foodborne Parasitic Diseases.

Authors:  Valeria A Sander; Edwin F Sánchez López; Luisa Mendoza Morales; Victor A Ramos Duarte; Mariana G Corigliano; Marina Clemente
Journal:  Front Cell Infect Microbiol       Date:  2020-06-26       Impact factor: 5.293

7.  Effective Nanoparticle-Based Nasal Vaccine Against Latent and Congenital Toxoplasmosis in Sheep.

Authors:  Céline Ducournau; Nathalie Moiré; Rodolphe Carpentier; Pauline Cantin; Clément Herkt; Isabelle Lantier; Didier Betbeder; Isabelle Dimier-Poisson
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.